I havent been posting for a while. I mentioned the random control trials for Pagaclone to a friend of mine, Gilles (PhD biopsychology), and told him that the trial might not really control for the placebo effect, because Pagaclone is an active compound and does change the brain chemistry. So the patients in the Pagaclone should experience (subtle) changes within themselves, and will know whether they are taking Pagaclone or not, and then they might have a secondary placebo effect: I am taking Pagaclone, so my speech will improve now.
Gilles suggested that the placebo should be a drug similar to Pagaclone, maybe an anti-anxiety drug, because then both groups (the Pagaclone and the control group) will experience a difference, and not know whether they are on Pagaclone or not.
Gilles suggested that the placebo should be a drug similar to Pagaclone, maybe an anti-anxiety drug, because then both groups (the Pagaclone and the control group) will experience a difference, and not know whether they are on Pagaclone or not.